Hospital
Public Health Trust of Miami Dade County Florida
Public Health Trust of Miami Dade County Florida was paid $15.92M by Medicaid between Jan 2018 and Dec 2024, across 229 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoPUBLIC HEALTH TRUST OF MIAMI DADE COUNTY FLORIDA
NORTH MIAMI BEACH, FL 33169
NORTH MIAMI BEACH, FL 33169
33aNPI1912932336assigned 07/12/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$15.92M
24GClaims607,783
24DCodes billed229
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in Florida
Rank by total paid#6 of 11
Median peer was paid$15.92M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KNIGHT, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,944 | $1.15M | |
| 2019 | 119,588 | $3.05M | |
| 2020 | 88,813 | $1.42M | |
| 2021 | 110,518 | $2.18M | |
| 2022 | 133,294 | $3.87M | |
| 2023 | 78,660 | $2.91M | |
| 2024incomplete | 32,966 | $1.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 32,927 | 30,304 | $3.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 33,169 | 29,289 | $2.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 19,320 | 15,837 | $1.60M |
| G0378 | Hospital observation service, per hour | 5.7% | 14,936 | 7,886 | $904K |
| 80053 | Comprehensive metabolic panel | 4.0% | 39,812 | 30,058 | $641K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.7% | 5,327 | 4,664 | $593K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 3,067 | 2,713 | $514K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 7,608 | 1,943 | $440K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 5,103 | 4,730 | $439K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 10,668 | 9,006 | $424K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 6,327 | 5,256 | $415K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 4,753 | 4,044 | $279K |
217 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 742 | $176K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 4,492 | $175K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,020 | $169K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,604 | $137K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 750 | $135K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,972 | $132K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,297 | $115K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 10,394 | $111K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,930 | $106K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 834 | $105K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,255 | $104K |
| 84703 | <1% | 15,251 | $103K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,055 | $101K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,428 | $94K |
| 87631 | <1% | 2,332 | $93K | |
| 86850 | <1% | 2,967 | $91K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 206 | $86K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,630 | $84K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,207 | $79K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,109 | $72K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,978 | $68K |
| 81001 | <1% | 27,324 | $63K | |
| 92587 | <1% | 1,497 | $58K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,747 | $54K |
| 84484 | <1% | 18,666 | $54K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,288 | $54K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,090 | $54K |
| 97162 | <1% | 2,282 | $52K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 145 | $49K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,886 | $43K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,263 | $37K |
| 84702 | <1% | 7,782 | $36K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 797 | $36K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,069 | $33K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 864 | $33K |
| 76801 | <1% | 1,846 | $30K | |
| 99205 | Prolong outpt/office vis | <1% | 487 | $29K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,484 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 760 | $26K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,549 | $24K |
| 85610 | <1% | 7,934 | $21K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 375 | $21K |
| 86900 | <1% | 3,641 | $20K | |
| 85730 | <1% | 6,645 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,561 | $19K |
| 83690 | <1% | 7,343 | $16K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 144 | $15K |
| 83735 | <1% | 4,754 | $15K | |
| 87040 | <1% | 4,458 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,291 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,116 | $14K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 177 | $14K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 981 | $13K |
| 93970 | <1% | 835 | $12K | |
| 73562 | <1% | 994 | $12K | |
| 72131 | <1% | 256 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,008 | $12K |
| 83880 | <1% | 4,396 | $11K | |
| 93971 | <1% | 677 | $11K | |
| 80061 | Lipid panel | <1% | 1,450 | $11K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,571 | $11K |
| 76830 | Ultrasound, transvaginal | <1% | 803 | $11K |
| 86803 | <1% | 8,534 | $11K | |
| 74018 | <1% | 897 | $11K | |
| 73030 | <1% | 782 | $10K | |
| 81003 | <1% | 1,362 | $10K | |
| 97010 | <1% | 230 | $10K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 230 | $10K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,467 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,235 | $9K |
| 83605 | <1% | 1,796 | $9K | |
| 73630 | <1% | 790 | $9K | |
| 87186 | <1% | 2,010 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,123 | $9K |
| 70486 | <1% | 238 | $9K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,455 | $8K |
| 86901 | <1% | 3,746 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,676 | $8K |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 321 | $8K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,364 | $8K |
| 82803 | <1% | 1,449 | $7K | |
| 87430 | <1% | 1,289 | $7K | |
| 82550 | <1% | 2,061 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,680 | $6K |
| 80320 | <1% | 3,129 | $6K | |
| 73130 | <1% | 409 | $6K | |
| 92586 | <1% | 107 | $6K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,654 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,421 | $5K |
| 72100 | <1% | 868 | $5K | |
| 86703 | <1% | 6,893 | $5K | |
| 73610 | <1% | 655 | $5K | |
| 85652 | <1% | 1,554 | $5K | |
| 82607 | <1% | 636 | $5K | |
| 97166 | <1% | 694 | $5K | |
| 87077 | <1% | 2,371 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,087 | $4K |
| 85379 | <1% | 1,473 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,417 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,388 | $4K |
| 84100 | <1% | 2,098 | $4K | |
| 94760 | <1% | 190 | $4K | |
| 86140 | <1% | 2,139 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,174 | $3K |
| 82553 | <1% | 523 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 952 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 699 | $3K |
| 95819 | <1% | 127 | $3K | |
| 80329 | <1% | 2,507 | $3K | |
| 96376 | <1% | 224 | $3K | |
| 97163 | <1% | 13 | $3K | |
| 82009 | <1% | 801 | $3K | |
| 0064U | <1% | 475 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,257 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,974 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 110 | $2K |
| 74022 | <1% | 179 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 75 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 856 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,187 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,209 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 448 | $2K |
| 87070 | <1% | 221 | $2K | |
| 86780 | <1% | 32 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,122 | $2K |
| 85007 | <1% | 1,240 | $1K | |
| 82746 | <1% | 219 | $1K | |
| 87340 | <1% | 787 | $1K | |
| 92558 | <1% | 183 | $1K | |
| 92523 | <1% | 14 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 669 | $1K |
| 73502 | <1% | 216 | $1K | |
| 82330 | <1% | 499 | $1K | |
| 82947 | <1% | 498 | $1K | |
| J3490 | Unclassified drugs | <1% | 1,467 | $1K |
| 76770 | <1% | 17 | $1K | |
| 73590 | <1% | 127 | $1K | |
| 84439 | <1% | 846 | $1K | |
| 73620 | <1% | 13 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 791 | $907.69 |
| 84132 | <1% | 591 | $800.18 | |
| 84295 | <1% | 426 | $783.44 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $779.79 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,034 | $770.33 |
| 12001 | <1% | 33 | $738.24 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 437 | $619.50 |
| 87205 | <1% | 136 | $602.24 | |
| 59025 | Fetal non-stress test | <1% | 86 | $593.15 |
| 73110 | <1% | 99 | $530.93 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 147 | $529.83 |
| 87807 | <1% | 215 | $525.02 | |
| 86923 | <1% | 40 | $442.05 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 813 | $439.83 |
| 97116 | <1% | 77 | $439.25 | |
| 93925 | <1% | 16 | $437.75 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 453 | $435.84 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 42 | $434.11 |
| 82150 | <1% | 98 | $433.02 | |
| 73090 | <1% | 60 | $406.33 | |
| 72040 | <1% | 64 | $392.54 | |
| 82435 | <1% | 224 | $391.97 | |
| 92650 | <1% | 62 | $391.59 | |
| 73552 | <1% | 15 | $335.01 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 17 | $309.80 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 205 | $298.75 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 194 | $282.26 |
| 74019 | <1% | 47 | $275.36 | |
| 83615 | <1% | 431 | $265.09 | |
| 81025 | <1% | 357 | $238.41 | |
| 90715 | <1% | 585 | $237.49 | |
| 82728 | <1% | 447 | $209.75 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 565 | $193.77 |
| A9270 | Non-covered item or service | <1% | 495 | $180.47 |
| J2704 | Injection, propofol, 10 mg | <1% | 182 | $179.06 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 96 | $173.26 |
| 80076 | <1% | 24 | $151.14 | |
| 84480 | <1% | 26 | $149.60 | |
| 71250 | <1% | 16 | $148.80 | |
| 92610 | <1% | 12 | $148.39 | |
| 36600 | <1% | 15 | $127.91 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 90 | $110.04 |
| 87210 | <1% | 44 | $98.22 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 39 | $94.32 |
| 84145 | <1% | 60 | $85.13 | |
| 00731 | <1% | 56 | $82.74 | |
| 85027 | <1% | 418 | $59.77 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 36 | $58.92 |
| 87641 | <1% | 77 | $51.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 315 | $41.37 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 291 | $41.37 |
| 80069 | <1% | 86 | $36.19 | |
| 00812 | <1% | 25 | $27.58 | |
| 86702 | <1% | 15 | $17.61 | |
| 88304 | <1% | 12 | $13.79 | |
| 86701 | <1% | 15 | $10.80 | |
| 83540 | <1% | 32 | $1.56 | |
| 83550 | <1% | 30 | $1.56 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 180 | $0.00 |
| 73080 | 0% | 13 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 58 | $0.00 |
| 92588 | 0% | 15 | $0.00 | |
| 85055 | 0% | 34 | $0.00 | |
| 85046 | 0% | 34 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 27 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 16 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 17 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 94 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 12 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 189 | $0.00 |
| 84436 | 0% | 40 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 22 | $0.00 |
| 87522 | Neg quan hep c or qual rna | 0% | 25 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 34 | $0.00 |
| 90686 | 0% | 16 | $0.00 | |
| 87640 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKNIGHT, MARK (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.